2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

Abstract Number: 561

U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Abstract Number: 225

U.S. Trends in Hospitalization Rates and Causes and in-Hospital Mortality in Rheumatoid Arthritis Patients, 2000-2014
Abstract Number: 1443

Ultrasonographic Criteria for the Diagnosis of Erosive Rheumatoid Arthritis Disease Using Osteoarthritic Patients As Controls Compared to Validated Radiographic Criteria
Abstract Number: 678

Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Abstract Number: 1632

Ultrasonographic Evaluation of the Enthesis in Patients Affected By Entheropatic Spondiloarthritis. Focus on Distal Enthesis of the Patellar Tendon
Abstract Number: 950

Ultrasonographic Examinations Show Highly Prevalent Abnormalities of Hamstring Tendons in Lyme Arthritis Patients
Abstract Number: 1206

Ultrasonographic Involvement of the Anterior Chest Wall,a Five Years Follow up
Abstract Number: 679

Ultrasonographic Research of the Relationship between Nail Disorders and Peripheral Arthritis or Enthesitis in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 2905

Ultrasound Diagnosis of Large Vessel Inflammation in New-Onset Treatment-Naïve GCA Patients Using Fluorine-18-Fluorodeoxyglucose PET/CT As the Reference Standard – a Prospective Study of 86 Patients Suspected of GCA
Abstract Number: 2966

Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Abstract Number: 1198

Ultrasound-Detected Joint Erosions in Rheumatoid Arthritis: What Every Sonographer Should Know
Abstract Number: 2530

Uncovering Clinicians’ Gaps and Attitudes Toward Biosimilars: Impact of a 2-Phase Educational Program
Abstract Number: 2362

Understanding Patients’ Perceptions of Gout
Abstract Number: 1096

Unexpected Association between Health-Related Quality of Life and the Blood Interferon Modular Transcriptional Signatures in Patients with Systemic Lupus Erythematosus
Abstract Number: 1200

Unilateral Ultrasound Scoring Methods for Synovitis in Rheumatoid Arthritis: An Agreement Study Exploring the Most Inflammatory Active Side
Abstract Number: 1528

Unique Changes in Hemoglobin with Sarilumab Versus Adalimumab Are Independent of Better Disease Control in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 109

Unique miRNA Signatures Detected in Extracellular Vesicles from Patients with Systemic Lupus Erythematous
Abstract Number: 1024

Unique Pattern of Lectin Pathway Complement Protein Levels in Axial Spondyloarthritis
Abstract Number: 409

Unique Skeletal Muscle Relaxant Tolperisone in a Crossover Driving Simulation Study: No Evidence of Sedation Compared to Cyclobenzaprine and Placebo
Abstract Number: 571

United States Rheumatology Practice-Based Real-World Evidence of Methotrexate Utilization and Response to Therapy in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab
Abstract Number: 680

Unmet Needs in the Treatment of Ankylosing Spondylitis. a Long-Term Observational Study from a Single University Center
Abstract Number: 549

Unmet Treat-to-Target Goals with Available Targeted Immunomodulators in the Management of Rheumatoid Arthritis: Real World Evidence from the Corrona Registry
Abstract Number: 889

Upadacitinib As Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Abstract Number: 2547

Upadacitinib Monotherapy Improves Patient-Reported Outcomes in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate
Abstract Number: 1425

Update from the Juvenile Scleroderma Inception Cohort
Abstract Number: 2254

Update of SEL-212 Phase 2 Clinical Data in Symptomatic Gout Patients: Svp-Rapamycin Combined with Pegadricase Mitigates Immunogenicity and Enables Sustained Reduction of Serum Uric Acid Levels, Low Rate of Gout Flares and Monthly Dosing
Abstract Number: 757

Urinary Galectin-3 Binding Protein As a Novel Biomarker of Renal Disease Activity in Lupus Nephritis
Abstract Number: 739

Urine and Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1) Differentially Correlates with Renal and Non-Renal Systemic Lupus Erythematosus (SLE): A Prospective, Case-Control Study
Abstract Number: 780

Urine Metabolomic Profile in Lupus Nephritis
Abstract Number: 2218

Use of Anakinra in Hospitalized Patients with Acute Crystalline Arthritis
Abstract Number: 1190

Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry
Abstract Number: 334

Use of Handheld Device to Enhance Patient Reported Outcome Measure Data Collection in an Academic Rheumatology Practice
Abstract Number: 329

Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Abstract Number: 344

Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Abstract Number: 2545

Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
Abstract Number: 2189

Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Abstract Number: 2371

Use of Social Media Among Patients with Rheumatic Diseases
Abstract Number: 819

Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Abstract Number: 1437

Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
Abstract Number: 1560

Usefulness of 18F-FDG Positron Emission Tomography for Lymphoma Diagnosis in Patients with Primary Sjögren’S Syndrome
Abstract Number: 1679

Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies
Abstract Number: 2213

Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears
Abstract Number: 2192

User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Abstract Number: 2103

Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Abstract Number: PP10

Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’
Abstract Number: 2699

Using ICD-10 Codes to Identify Patients with Systemic Sclerosis in the Electronic Health Record
Abstract Number: 1692

Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record
Abstract Number: 859

Using Online Simulation of Pediatric Musculoskeletal Cases to Evaluate How Knowledge of Costs Affects Diagnostic Workup
Abstract Number: 1408

Using Patient Reported Outcomes at Point of Care in Immune Mediated Diseases: Minimal Clinically Important Differences
Abstract Number: 251

Using the Stroop Word Naming Test and the Mental Clutter Scale in Fibromyalgia Patients to Evaluate the Symptoms of Fibrofog. in Office Testing of Cognitive Complaints
Abstract Number: 2951

Ustekinumab Treatment Response in SLE Is Associated with Changes in Type II but Not Type I Interferons
Abstract Number: 2828

Utility of Fecal Calprotectin Levels for the Diagnosis of Inflammatory Bowel Disease in Patients with Spondylorarthritis
Abstract Number: 2612

Utility of Infiltration with Steroids in Dactilitis. Is the Infiltration Guided By Ecography Better THAN Conventional?
Abstract Number: 2750

Utility of Methotrexate in Polymyalgia Rheumatica
Abstract Number: 1504

Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Abstract Number: 2763

Utility of Serum Free Light Chains, Antiphospholipid Antibodies, and Cytokines in Giant Cell Arteritis
Abstract Number: 1702

Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease
Abstract Number: 1711

Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Abstract Number: 2755

Utility of Tocilizumab in Visual Affection of Patients with Giant Cell Arteritis
Abstract Number: 1709

Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Abstract Number: 2101

UV-Induced Skin Inflammation Is Exacerbated in Lupus-Prone Ro60 Knockout Female Mice with Interferon Priming
Abstract Number: 1639

Uveitis As First Symptom in Patients with Spondyloarthritis. Data from the Spanish Registry Regisponser
Abstract Number: 1647

Uveitis, the Most Faithful Partner of Axial Spondyloarthritis

Jump to: View All • a b c d e f g h i j k l m n o p q r s t [u] v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].